The shadow of generic competition has consistently loomed around copyright’s famous drug, Viagra, raising questions about the future of connected medicinal investments. While early times saw impressive profits, the patent end has created the door for cheaper alternatives, possibly lowering profitability and creating a real danger for stakeholders